The Shigella Vaccines Pipeline

Shigella is the leading cause of global diarrheal deaths that currently lacks a licensed vaccine. Shigellosis drives antimicrobial resistance and leads to economic impact through linear growth faltering. Today, there is a robust pipeline of vaccines in clinical development which are broadly divided...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2022-08, Vol.10 (9), p.1376
Main Authors: MacLennan, Calman Alexander, Grow, Stephanie, Ma, Lyou-fu, Steele, Andrew Duncan
Format: Article
Language:English
Subjects:
Antibiotics
Antibodies
Antigens
Antimicrobial resistance
Clinical trials
Diarrhea
Dysentery
Economic impact
Epidemics
Fatalities
flexneri
glycoconjugate
Immunogenicity
Immunology
Impact analysis
Infections
Mutation
Review
Shigella
Shigellosis
sonnei
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Shigella is the leading cause of global diarrheal deaths that currently lacks a licensed vaccine. Shigellosis drives antimicrobial resistance and leads to economic impact through linear growth faltering. Today, there is a robust pipeline of vaccines in clinical development which are broadly divided into parenteral glycoconjugate vaccines, consisting of O-antigen conjugated to carrier proteins, and oral live attenuated vaccines, which incorporate targeted genetic mutations seeking to optimize the balance between reactogenicity, immunogenicity and ultimately protection. Proof of efficacy has previously been shown with both approaches but for various reasons no vaccine has been licensed to date. In this report, we outline the requirements for a Shigella vaccine and describe the current pipeline in the context of the many candidates that have previously failed or been abandoned. The report refers to papers from individual vaccine developers in this special supplement of Vaccines which is focused on Shigella vaccines. Once readouts of safety and immunogenicity from current trials of lead candidate vaccines among the target population of young children in low- and middle-income countries are available, the likely time to licensure of a first Shigella vaccine will become clearer.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines10091376